ERVOUS system repair has become a serious therapeutic goal and the target of intensive basic and clinical research. Cellular repair of the human CNS poses significant scientific, translational, regulatory, and ethical issues. The challenges in the early trial design and implementation of stem cell-based transplantation to treat neurodegenerative disorders are measurable. Fortunately each area of cell transplantation therapy is being actively addressed by academic and industry groups, and interest continues to grow.
Successful Neural Transplantation Requires Choosing the Right Host and Donor Cells

Choosing the Ideal Host
A variety of developmental, degenerative, and traumatic neurological diseases are considered candidates for cell replacement therapy. These diverse disease processes differ in the types or groups of cells involved in the pathology of the disease. Consequently the cells used for replacement in each condition will depend upon the affected cell population and resultant need of the organism. Historically, the research and clinical spotlight has been directed toward neuronal replacement in the CNS to treat neurodegenerative conditions such as PD. This places high demands on transplanted precursor cells, with a critical requirement being functional integration of grafted cells into endogenous neuronal circuitry. The donor cell, in this situation, must terminally differentiate into the correct neurotransmitter subtype with regional specificity, establish correct functional afferent and efferent synaptic connections, and resist the disease process which caused the death of the endogenous neurons. A simpler model, placing fewer demands on donor cells, would be a neurological condition that requires only the survival of donor cells and the secretion of a normal gene product. Lysosomal storage disorders are an example, and in many ways these are the ideal models for taking the first steps in neural transplantation. The goal of NSC therapy in these cases is to achieve dispersement of transplanted cells throughout the brain parenchyma and secretion of appropriate enzymes by the transplanted cells. Deficient host neurons can then take up the enzymes by receptor-mediated endocytosis, and incorporate them into the lysosomes where they can then normalize lysosomal function, reduce or eliminate precursor accumulation, and protect neurons from degeneration.
Choosing the Ideal Donor Cells
In a general sense, the ideal donor cells should be easy to obtain or produce in large numbers, effective in cellular or molecular replacement, tolerant to immune rejection, and resistant to generation of aberrant (neoplastic) tissue. To obtain a large number of human donor cells, in vitro expansion is required. The cells are generally expanded at an immature or progenitor stage. Although cells can be isolated at any point along their developmental path, it should be kept in mind that the developmental stage of the organism donating the cells will strongly influence the potential and limitations of the donor cell population. At earlier lineage stages, cells are thought to possess a greater capacity for proliferation, migration, differentiation, and tumor formation. Cells at later lineage stages, although safer, have a lower capacity for expansion, migration, and differentiation. 15 Most current strategies isolate cells in the progenitor stages, during which they can then undergo purification and/or directed differentiation. 26, 30, 40 In the organism, ESCs appear as the inner cell mass of the preimplantation (blastocyst) embryo. These cells go on to form all of the tissue types of the organism in a specific spatial and temporal order. Establishment of human ESCs has offered an unprecedented source of human cells for multiple applications including studies of human development, gene discovery, and the production of specialized neural progenitor cells that may be used for cell replacement. 9, 35 However, because ESCs carry the highest degree of pluripotency, their use as transplanted cells would almost certainly result in teratoma formation. In reality, ESCs have been most useful as a means of studying the pathways of human development, and more work must be done before they can be considered safe or effective as a starting source of transplantable cells (see Zhang et al. 40 2008 for review). A realistic strategy for the creation of safe and effective transplantable cells to be used for CNS enzyme replacement therapy is purification and enrichment of progenitor, or neural, stem cells that have been isolated at a later lineage stage. These cells can be expanded in vitro and are then able to differentiate further into neurons, astrocytes, and oligodendrocytes. 12, 41 For a group of diseases such as the lysosomal storage disorders, these donor cells are likely to be safe and effective as a vehicle for delivering or supplementing missing molecules such as growth factors and enzymes.
Establishing the Safety and Efficacy of Transplantable Cells Prior to Clinical Trials
Any transplantable cell that is more than "minimally manipulated" is subject to the statutes described in the Public Health Safety Act, Section 361 (for human cells) and Section 351 (for biological products). These laws require the submission of an investigational new drug application to the FDA before studies involving humans are initiated. 17 Products that are banked, transported, or processed are at risk for contamination, and these statutes exist to prevent the use of contaminated tissues, limit the improper handling of tissues, and ensure the clinical safety and efficacy of cells or tissues that "are highly processed, are used for something other than their normal function, are combined with non-tissue components, or are used for metabolic purposes." 17 The manufacturer of a biological product must demonstrate that it is safe, pure, and potent. To license a biological product, an application for a biological license must be approved by the FDA, and approval requires sufficient data demonstrating that the investigational product is safe and effective in humans. The regulatory aspects of cell transplantation are covered in more detail in Part II of this manuscript.
The safety of a transplanted cell population is largely determined by the purity of the population. In stem cell biology, safety concerns are predominantly focused on contamination of a cell population by immature stem cells that can proliferate in an uncontrolled manner, forming tumors. 4, 5 Other concerns deal with infection and genetic alteration. Fluorescence-activated cell sorting and immunomagnetic separation techniques are used to isolate live cells that rely on particular cell-surface expression profiles. After sorting, purity can be assessed by immunolabeling for specific antigens and in animal testing.
The efficacy of a transplanted cell population generally requires in vivo studies with results suggesting that the cell will perform a required task (such as the production of a particular enzyme) and animal studies demonstrating functional improvement.
Demonstrating the Safety and Efficacy of Human NSCs in Preclinical Investigations
Preclinical testing of a human NSC line is a complex process. In vitro strategies include isolation and purification, expansion, predifferentiation and/or directed terminal differentiation, and techniques to test efficacy (enzyme or neurotransmitter secretion or action potential propagation). In vivo studies focus on cell survival, cell dispersement, proof of appropriate cellular function (through enzyme secretion, neurotransmitter release, and integration), tumor formation, and ultimately, functional improvement.
Human NSCs are initially derived from human fetal brain tissue. After enzymatic dissociation, NSCs can be isolated by fluorescence-activated cell sorting and grown in culture as free-floating neurospheres in specific growth factor-rich media. After fluorescence-activated cell sorting, neural progenitor cells can then be expanded in culture, retaining their ability to reinitiate neurosphere formation. 31, 34 Cells obtained this way have been extensively studied and have been found 1) to display a normal karyotype, 2) not to form tumors in vivo, 3) not to require predifferentiation with specific factors, and 4) to retain pluripotentiality. 13, 14, 34, 36 If cells are to be used as enzyme-secreting factories for enzyme-deficiency disorders, appropriate enzyme synthesis and secretion must be demonstrated both in vitro and in vivo. In animal models, transplanted human NSCs have been shown to secrete appropriate missing enzymes for mucopolysaccharidosis Type VII, 29 neuronal ceroid lipofuscinoses Types 1 and 2, 34 Niemann-Pick disease, 1 and others. 8, 27 Dispersement of grafted cells is an important element of treatment in any disease that affects cells in every region of the brain. Human NSCs transplanted into newborn nonobese diabetic/severe combined immunodeficient (NOD/ SCID) mice demonstrate extensive engraftment, site-specific proliferation, and migration for up to 7 months after transplantation. These cells respond to host environmental cues and appropriately differentiate into neurons, astrocytes, and oligodendrocytes in a region-specific manner. 7, 33, 36 The final preclinical studies deal with proper in vivo cellular function, behavioral improvement, and safety. After transplantation into enzyme-deficient rodent models, human NSCs have been shown to survive, migrate, secrete enzymes for up to 6 months throughout the brain, and cause a reduction in lysosomal storage material associated with disease pathology when compared with controls in several brain regions and in a number of animal models. 1, 3, 8, 27, 29, 34 Lack of tumor formation for up to 1 year after transplantation has been demonstrated. 36 These important preclinical studies provide proof-of-concept that further support Phase I clinical trial investigations of the safety and efficacy of human NSC therapy for CNS enzyme replacement.
Noninvasive Monitoring of Transplanted Cells
Currently, there is no validated method available for tracking NSCs in human patients after transplantation. The ideal imaging technique for tracking NSCs would yield high temporal and spatial resolution, good sensitivity and specificity, and most importantly, would be safe. The ability to track the cells in vivo will provide important information on the safety, outcome, and potential clinical usefulness of CNS stem cell transplantation, including location after implantation, migration, and viability.
There have been some recent important and exciting advances in the science of cell tracking. Guzman and colleagues 16 recently reported successful labeling of human NSCs grown as neurospheres with magnetic nanoparticles allowing detection on MR imaging in rodents. This approach expanded on earlier studies that used nonhuman cells and paramagnetic particles pioneered for potential use in human disease by Neuwelt and others. 23 The approach taken by Guzman's group did not adversely affect survival, migration, or differentiation of the cells, nor did it alter neuronal electrophysiological characteristics. Stem cells labeled using their technique survived in the long term and differentiated in a site-specific manner identical to that seen with transplants of unlabeled cells. Implementation of noninvasive stem cell tracking will advance the design of future clinical trials using NSC transplantation.
Although this approach has yet to be applied to transplantation in humans, it does appear to be feasible, particularly given that some paramagnetic particles have already received FDA approval. Other techniques for noninvasive imaging of stem cells have been considered including nuclear medicine techniques, fluorescence, and bioluminescence, but an MR-based imaging platform has many advantages, including wide availability and an outstanding safety record. Scintigraphic imaging and positron emission tomography are currently available for tracking cells but provide insufficient spatial resolution to be useful in this setting. Bioluminescence and fluorescence are not suitable for use in humans with current technology. Recently, a metabolic biomarker was described that can be used to detect and quantify NSCs in the human brain. 21 This biomarker, enriched in NSCs, can be identified using proton nuclear MR spectroscopy. However, because this biomarker dramatically decreases with cell age, 21 it is not clear whether it will be detectable following differentiation and maturation of stem cells.
Magnetic resonance imaging of stem cells was recently reviewed. 28 Investigators are also studying the possibility of using viral vectors to deliver genes to stem cells encoding proteins detectable on MR imaging. Genes encoding such proteins, referred to as MR reporter genes, while making transplanted NSCs inherently imageable, also add additional regulatory considerations to future clinical trial approval because they require the use of genetically altered cells.
Immunology of CNS Allogenic Transplantation
The immunology of CNS allogenic transplantation is a complex and incompletely understood subject. The CNS has been regarded as an immunologically privileged site based on the historically held concepts of an impermeable BBB, minimal lymphatic drainage, and lack of efficient resident APCs. Early investigators recognized the unique status of the brain for survival of allograft and xenograft transplants. 37 In addition, the prolonged survival of cellular and tissue grafts in patients with PD who received fetal nigral tissue allografts has supported the premise that the brain is a relatively immunoprivileged site.
This privilege, however, is not absolute. The results of recent studies indicate that the BBB is breached by activated lymphocytes, that resident microglia have antigen-presenting capacity, and that there is a small but measurable degree of CNS lymphatic drainage into the deep cervical lymph nodes. Thus, it is more accurate to view the brain as a site that permits prolonged allogenic engraftment, rather than one of absolute immunoprivilege. The factors allowing long-term CNS engraftment and the mechanisms triggering rejection require further investigation. 2, 20, 37 When it occurs, the immune rejection process is dependent on disparity between the host and donor variable portions of MHC I and II molecules. The MHC complex genes code for membrane-bound glycoproteins, which are expressed as HLA-A, HLA-B, and HLA-C for Class I, and HLA-DO, HLA-DP, HLA-DQ, and HLA-DR for Class II. The MHC disparity in xenografts and allografts results in a rejection process that relies on host cellular and humoral responses, and is proportional to species distance between donor and host. The immune system recognizes foreign antigens on donor tissue and cells as "altered-self." Foreign MHC molecules bind to T-cell receptors, activating immune system effector mechanisms including directed proliferation of helper T cells and killer T cells, as well as antibody formation by B cells. The immune activation process is also associated with the production of cytokines including interleukins 1 and 2, and ␥-interferon by the associated T-cell populations and host APCs, resulting in coordinated proliferation of immune cells.
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In the CNS, the important host APCs are the resident microglia and the bone marrow-derived perivascular microglia. Each can respond to stimuli associated with allogenic transplantation and result in either MHC or non-MHC antigen presentation to host T-cell receptors and subsequent activation of the immune system. The immune activation process also involves costimulatory ligands, which reinforce T-cell responses to the foreign MHC/antigen peptide complexes. The key cellular elements of graft rejection are the T lymphocytes (CD4+ and CD8+) and resident microglial cells. The systemic immune response then incorporates helper, effector, and killer T cells in a coordinated response to the donor tissue antigens. Failure of this activation sequence results in T-cell anergy and the possibility of partial tolerance to the graft.
In addition, other physical factors may contribute to immune surveillance of CNS allografts, including the number of donor cells, the degree of disruption of the BBB during transplantation, the route and technique of transplantation, and the location of the transplant within the CNS.
Neural grafting has been performed in the setting of controlled prospective trials with and without immunosuppression. 10, 25 Although it is controversial, most investigators suggest that some form of immunosuppression is necessary to optimize engraftment and survival of donor cells. The goal of immunosuppression is to suppress host immune responses by blocking T-cell activation. This is probably best accomplished at the time of cellular transplantation because of the acute disruption of the BBB associated with the transplantation technique. The most commonly used immunosuppressive agents are cyclosporin-A and FK-506. Both are immunophilins that inhibit calcineurin, prevent phosphorylation of a nuclear transcription factor, and ultimately block T-cell cytokine expression and production. There is no consensus regarding the optimal agent or combination thereof, duration, dose, or level of immunosuppression to accompany CNS allograft transplantation. However, upcoming clinical trials of both ESC-derived and somatic stem cell transplantations are likely to incorporate a limited course of immunosuppression designed to block T-cell activation.
Clinical aspects of immunosuppression have been best studied in transplantation trials involving fetal nigral dopaminergic cells in patients with PD. 10, 25 Postmortem examinations of patients who received transplanted cells have been conducted in 2 prominent prospective randomized controlled trials. 10, 25 A total of 6 patients, 2 without and 4 with immunosuppression, have undergone detailed postmortem examination. Each showed persistence of grafted cells, in some cases long after the initial immunosuppression therapy was discontinued. 10, 25 However, detailed analysis also revealed markers of immune response surrounding the field of donor cells, including T cells, B cells, macrophages, and activated microglia. Similar findings were also documented in 2 different studies of fetal tissue allograft transplantation for Huntington disease, 11, 19 showing evidence of long-term engraftment and parallel immune marker expression within the graft site. Cell survival was also identified in the clonal human neuron trial for stroke (with 8 weeks of immunosuppression) in which the implanted neurons were demonstrated to have survived 27 months after transplantation in a 71-year-old man. 22 The presence of immune cells within the region of grafted cells was not described in this case report. The significance of the dual presence of donor cells and immune response in most postmortem studies is unclear; several interpretations of the data have been offered, including the possibility of chronic low-grade rejection, or the possibility that the adjacent immune response provided a supportive role for the engrafted cells.
In either case, the presence of immune cells within engrafted tissues argues that the CNS does not enjoy absolute immunoprivilege. The applicability of postmortem results from studies of fetal tissue transplantation to trials using highly purified and expanded NSC allografts is uncertain. The immunogenicity of fetal dopaminergic cells has not been systematically compared to that of neural stem/progenitor cells. Nonetheless, the presence of allograft cells well beyond the time of transplantation supports the concept of prolonged engraftment and possibly long-term CNS immunotolerance, enhancing the therapeutic potential of CNS cellular transplants in the clinical setting.
The ability to achieve prolonged survival of functional CNS cellular allografts will depend on clarifying factors that contribute to immune-mediated rejection and those that contribute to immunotolerance. The use of immunosuppression poses multiple risks for patients, and a better understanding of the mechanisms underlying rejection and successful long-term engraftment are important to advancing the field of CNS transplantation. The ability to monitor engraftment through noninvasive measures will also refine the use of immunosuppression and contribute to our understanding of the immunological characteristics of CNS transplantation. Informed utilization of immunosuppression will maximize patient safety, promote cellular engraftment, and ultimately allow transplanted cells to produce beneficial biological effects in patients.
In the future, immunosuppression may be avoided by an alternative strategy that involves generation of cells that are genetically identical to the patient. 18, 39 Transfer of nuclear factors from the oocyte into somatic cells can reprogram fully differentiated somatic cells to a pluripotent state. Such stem cells have been induced from mouse fibroblasts by retroviral introduction of Oct3/4, Sox2, c-myc, and Klf4. 32 These induced pluripotent stem cells are similar to ESCs in terms of their capacity for expansion and their differentiation potential. 24, 32 Using a similar approach, adult rhesus macaque fibroblasts were used to produce 2 primate ESC lines. 6 Recently, human somatic cell nuclei were reprogrammed to pluripotent stem cells that exhibit the essential characteristics of ESCs using Oct4, Sox2, Nanog, and Lin28. 38 This exciting new technology may offer a way to provide stem cells with enormous differentiation potential that avoids many immunological and practical constraints.
Conclusions
Stem cell therapy for the human CNS is an extraordinarily complex undertaking in scientific, regulatory, and ethical terms. However, for certain serious diseases, stem cell therapy appears to offer the greatest current potential for effective treatment. Progress in this vital area requires the coordinated efforts of scientists, clinicians, surgeons, clinical trials professionals, industry representatives, regulatory bodies, ethical specialists, and public stakeholders.
